Want to see EOCN full AI Analyst Report?
Top Page
Eocene
(NASDAQ:EOCN)
Select Model
Select Model
Rating:44Neutral
Price Target:
$3.00
▼(-30.23% Downside)
Action:Reiterated
Date:09/11/26
The score is primarily weighed down by weak financial performance (pre-revenue operations, ongoing losses, and higher recent cash burn), with only limited offset from low leverage. Technicals add further pressure as the stock trades below major moving averages with a negative MACD. Valuation is also challenged due to negative earnings (negative P/E) and no provided dividend yield.
Positive Factors
Low Leverage
Minimal debt limits interest obligations and reduces solvency pressure while the company funds clinical development. This conservative leverage profile preserves flexibility to allocate capital toward research, trials, and other priorities without carrying a large fixed repayment burden.
Negative Factors
Pre-Revenue Model
The absence of revenue means operations are not yet supported by product sales or recurring commercial cash inflows. Financial performance therefore depends on successful clinical development and future funding, leaving earnings power and business sustainability highly uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Minimal debt limits interest obligations and reduces solvency pressure while the company funds clinical development. This conservative leverage profile preserves flexibility to allocate capital toward research, trials, and other priorities without carrying a large fixed repayment burden.
Read all positive factors
Eocene (EOCN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.33M
Dividend YieldN/A
Average Volume (3M)7.66K
Price to Earnings (P/E)―
Beta (1Y)1.68
Revenue GrowthN/A
EPS Growth68.55%
CountryUS
Employees6
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-13.82
Shares Outstanding1,041,565
10 Day Avg. Volume6,574
30 Day Avg. Volume7,655
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.51
Enterprise Value/Market Cap-3.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-12.48
Revenue Forecast (FY)$5.72M
Eocene Business Overview & Revenue Model
Company Description
Eocene Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bil...
How the Company Makes Money
As a clinical-stage company, Galmed has historically not relied on recurring revenue from marketed products; public information indicates its operations are primarily funded through financing activities such as issuing equity (public offerings/ATM...
Eocene Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Eocene Technical Analysis
Negative
4.30
Price Trends
3.63
Negative
4.06
Negative
4.62
Negative
Market Momentum
-0.16
Negative
46.31
Neutral
84.68
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EOCN, the sentiment is Negative. The current price of 4.3 is above the 20-day moving average (MA) of 3.22, above the 50-day MA of 3.63, and below the 200-day MA of 4.62, indicating a bearish trend. The MACD of -0.16 indicates Negative momentum. The RSI at 46.31 is Neutral, neither overbought nor oversold. The STOCH value of 84.68 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EOCN.
Eocene Risk Analysis
Eocene disclosed 77 risk factors in its most recent earnings report. Eocene reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Eocene Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | $8.25M | -0.28 | -304.87% | ― | ― | 98.98% | |
44 Neutral | $3.33M | -0.34 | -73.68% | ― | ― | 68.55% | |
42 Neutral | $6.58M | -0.04 | 952.76% | ― | -21.49% | 84.62% | |
41 Neutral | $2.58M | -0.01 | -372.86% | ― | ― | 53.95% | |
40 Underperform | $4.88M | ― | 762.51% | ― | 135.52% | 85.50% |
* General Sector Average
EOCN
Eocene
3.20
-7.52
-70.15%
AIM
AIM ImmunoTech
0.17
-2.05
-92.56%
JAGX
Jaguar Animal Health
2.10
-749.78
-99.72%
QNRX
Quoin Pharmaceuticals
4.11
-7.31
-64.01%
SILO
Silo Pharma
1.34
-6.97
-83.88%
CLDI
Calidi Biotherapeutics
0.70
-24.58
-97.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.